Accelerate Diagnostics (AXDX) Tops Q3 EPS by 19c

Accelerate Diagnostics (NASDAQ: AXDX) reported Q3 EPS of $0.06, $0.19 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $3.98 million.

For earnings history and earnings-related data on Accelerate Diagnostics (AXDX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Reading (RDI) Tops Q2 EPS by 4c